AGIO 84.03 Agios Pharmaceuticals Inc $AGIO Hit a 5
Post# of 83
Posted On: 11/01/2014 10:07:16 PM
AGIO 84.03 Agios Pharmaceuticals Inc $AGIO Hit a 52 week high of 88.82 Closing the day 10/31/14 at 84.03 -0.34 -0.40% With a day low of 82.85 and a total volume of 785,800.
AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/
AGIO Agios Pharmaceuticals Inc Recent Headline News
'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 46.93 (-0.54), RICE: 26.43 (+1.21), GS: 189.99 (+3.02), FEYE: 33.99 (+0.36), ISIS: 46.06 (+0.18), CYBR: 35.28 (+0.57), GNC: 41.57 (-1.33), HAL: 55.14 (+1.22), EOG: 95.05 (+2.83), AGIO: 84.03 (-0.34), FTNT: 26.05 (+0.31)
Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 54.22 (-0.58), FEYE: 33.99 (+0.36), CYBR: 35.28 (+0.57), FB: 74.99 (+0.88), GNC: 41.57 (-1.33), HAL: 55.14 (+1.22), AGCO: 44.31 (+0.36), BWLD: 149.28 (-0.76), MAS: 22.07 (+0.27), YHOO: 46.05 (+0.42), WHR: 172.05 (+1.50), VSI: 46.93 (-0.54), SAVE: 73.11 (+2.21), RICE: 26.43 (+1.21), GS: 189.99 (+3.02), PH: 127.03 (+2.36), ISIS: 46.06 (+0.18), CMI: 146.18 (+1.56), EOG: 95.05 (+2.83), AGIO: 84.03 (-0.34), TWTR: 41.47 (-0.33), FTNT: 26.05 (+0.31), BABA: 98.60 (-0.13)
Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 20.77 (-1.38), AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 44.95 (+0.18), NVAX: 5.60 (-0.03), AGIO: 84.03 (-0.34), SNY: 46.24 (+0.54), MNKD: 6.01 (-0.07), CELG: 107.09 (+0.15)
Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 84.03 (-0.34)
3 Momentum Stocks to Watch in Biotechnology for Continued Upside
at The Street - Thu Oct 23, 2:39PM CDT
Wednesday was a strong session for a number of stocks, and here are three, in particular, to watch for more upside.
BABY: 34.00 (+0.13), RGLS: 19.96 (+1.66), AGIO: 84.03 (-0.34)
Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
GlobeNewswire - Tue Oct 21, 7:39AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation. The study will enroll patients who have recurred or progressed following standard therapy or have not responded to prior standard therapy. This is the second trial to be initiated in patients with cancer as part of AG-221's clinical development program, which includes the ongoing Phase 1 trial with four expansion cohorts in patients with hematologic malignancies.
AGIO: 84.03 (-0.34)
Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 105.70 (+2.96), EBS: 22.62 (+0.27), AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221
GlobeNewswire - Wed Oct 15, 6:30AM CDT
Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies
AGIO: 84.03 (-0.34)
Insider Trading Alert - AGIO, ACN And CTAS Traded By Insiders
at The Street - Mon Oct 06, 9:06AM CDT
Stocks with insider trader activity include AGIO, ACN and CTAS
CTAS: 73.24 (+0.55), AGIO: 84.03 (-0.34), ACN: 81.12 (+0.50)
Agios Pharmaceuticals to Webcast R&D Day on October 15, 2014
GlobeNewswire - Mon Oct 06, 8:33AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will webcast presentations at its Research and Development (R&D) Day on Wednesday, October 15, 2014, from 9:00 a.m. to approximately 12:00 p.m. EDT in New York City.
AGIO: 84.03 (-0.34)
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter
PR Newswire - Wed Oct 01, 7:55AM CDT
Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Amgen Inc. (NASDAQ: AMGN), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6893-100free.
BIIB: 321.08 (+0.08), BAX: 70.14 (+0.08), COV: 92.44 (+0.83), AMGN: 162.18 (+0.60), AGIO: 84.03 (-0.34)
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
MDVN: 105.70 (+2.96), GILD: 112.00 (-2.22), AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Critical Alerts For Invensense, Agios Pharmaceuticals, SPDR Gold Trust, Nu Skin Enterprises and Nike Released By InvestorsObserver
PR Newswire - Mon Sep 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INVN, AGIO, GLD, NUS and NKE.
NKE: 92.97 (-0.03), NUS: 52.83 (+0.01), GLD: 112.66 (-2.53), INVN: 16.21 (+0.54), AGIO: 84.03 (-0.34)
Market Maker Surveillance Report. SKY, JNS, CNET, DGLY, AGIO, SFS, Winning Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Skyline Corp (NYSE:SKY), Janus Capital Group Inc (NYSE:JNS), Chinanet Online Holdings Inc (NASDAQ:CNET), Digital Ally Inc (NASDAQ
GLY), (NASDAQ:AGIO), (NYSE:SFS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SFS: 14.75 (+0.75), SKY: 3.78 (-0.02), JNS: 14.99 (+0.32), AGIO: 84.03 (-0.34), CNET: 2.10 (-0.01), DGLY: 14.62 (-0.07)
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
MU: 33.09 (+1.27), HYG: 92.53 (+0.08), NKE: 92.97 (-0.03), XOP: 60.87 (+1.70), PFE: 29.95 (+0.11), BBRY: 10.50 (+0.02), XOM: 96.71 (+2.26), WYNN: 190.01 (+2.36), LVS: 62.26 (+0.76), MO: 48.34 (+0.84), BMY: 58.19 (-0.79), EWM: 15.37 (-0.04), TLT: 119.25 (-0.31), CELG: 107.09 (+0.15), JNK: 40.36 (unch), YHOO: 46.05 (+0.42), GILD: 112.00 (-2.22), AOL: 43.53 (+0.61), AGIO: 84.03 (-0.34), FL: 56.01 (+0.16), XLE: 87.42 (+1.74), BABA: 98.60 (-0.13)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Sep 26, 7:14PM CDT
Cramer will be looking for more opportunities, especially ones made better by any additional volatility.
F: 14.09 (+0.14), MKC: 70.72 (+0.86), NKE: 92.97 (-0.03), INVN: 16.21 (+0.54), M: 57.82 (-0.08), GLUU: 3.87 (+0.26), BWLD: 149.28 (-0.76), SLB: 98.66 (+1.04), YHOO: 46.05 (+0.42), ESRT: 15.96 (+0.05), AAPL: 108.00 (+1.02), WAG: 64.22 (+1.26), ECL: 111.23 (+2.88), HCP: 43.97 (+0.38), SWKS: 58.24 (+2.20), HAL: 55.14 (+1.22), STZ: 91.54 (+2.13), MGM: 23.25 (+0.27), FINL: 26.47 (+0.07), ADS: 283.35 (+0.38), TTWO: 26.45 (+1.18), WPG: 17.63 (+0.14), WEX: 113.56 (+2.31), KITE: 36.99 (+1.25), AOL: 43.53 (+0.61), FLT: 150.56 (+8.01), AGIO: 84.03 (-0.34), MRO: 35.40 (+1.29)
Agios drug data boosts stock
at Investor's Business Daily - Fri Sep 26, 5:52PM CDT
Biotech startup Agios Pharmaceuticals (AGIO) got a 19.3% boost to a new high of 63.76 after the company said that it would release key clinical trial data from its phase 1 study of blood cancer treatment AG-120 earlier than anticipated. It's...
AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Agios' Early Drug-Trial Report Cheers Wall Street
at Investor's Business Daily - Fri Sep 26, 12:21PM CDT
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good....
AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 26, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NAII: 6.12 (+0.02), TNXP: 7.57 (-0.43), MSON: 13.36 (+0.08), RPRX: 6.34 (-0.41), CCRN: 9.67 (+0.06), AGIO: 84.03 (-0.34), CMSB: 12.90 (-0.10), DGLY: 14.62 (-0.07)
AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/
AGIO Agios Pharmaceuticals Inc Recent Headline News
'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 46.93 (-0.54), RICE: 26.43 (+1.21), GS: 189.99 (+3.02), FEYE: 33.99 (+0.36), ISIS: 46.06 (+0.18), CYBR: 35.28 (+0.57), GNC: 41.57 (-1.33), HAL: 55.14 (+1.22), EOG: 95.05 (+2.83), AGIO: 84.03 (-0.34), FTNT: 26.05 (+0.31)
Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 54.22 (-0.58), FEYE: 33.99 (+0.36), CYBR: 35.28 (+0.57), FB: 74.99 (+0.88), GNC: 41.57 (-1.33), HAL: 55.14 (+1.22), AGCO: 44.31 (+0.36), BWLD: 149.28 (-0.76), MAS: 22.07 (+0.27), YHOO: 46.05 (+0.42), WHR: 172.05 (+1.50), VSI: 46.93 (-0.54), SAVE: 73.11 (+2.21), RICE: 26.43 (+1.21), GS: 189.99 (+3.02), PH: 127.03 (+2.36), ISIS: 46.06 (+0.18), CMI: 146.18 (+1.56), EOG: 95.05 (+2.83), AGIO: 84.03 (-0.34), TWTR: 41.47 (-0.33), FTNT: 26.05 (+0.31), BABA: 98.60 (-0.13)
Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 20.77 (-1.38), AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 44.95 (+0.18), NVAX: 5.60 (-0.03), AGIO: 84.03 (-0.34), SNY: 46.24 (+0.54), MNKD: 6.01 (-0.07), CELG: 107.09 (+0.15)
Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 84.03 (-0.34)
3 Momentum Stocks to Watch in Biotechnology for Continued Upside
at The Street - Thu Oct 23, 2:39PM CDT
Wednesday was a strong session for a number of stocks, and here are three, in particular, to watch for more upside.
BABY: 34.00 (+0.13), RGLS: 19.96 (+1.66), AGIO: 84.03 (-0.34)
Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
GlobeNewswire - Tue Oct 21, 7:39AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation. The study will enroll patients who have recurred or progressed following standard therapy or have not responded to prior standard therapy. This is the second trial to be initiated in patients with cancer as part of AG-221's clinical development program, which includes the ongoing Phase 1 trial with four expansion cohorts in patients with hematologic malignancies.
AGIO: 84.03 (-0.34)
Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 105.70 (+2.96), EBS: 22.62 (+0.27), AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221
GlobeNewswire - Wed Oct 15, 6:30AM CDT
Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies
AGIO: 84.03 (-0.34)
Insider Trading Alert - AGIO, ACN And CTAS Traded By Insiders
at The Street - Mon Oct 06, 9:06AM CDT
Stocks with insider trader activity include AGIO, ACN and CTAS
CTAS: 73.24 (+0.55), AGIO: 84.03 (-0.34), ACN: 81.12 (+0.50)
Agios Pharmaceuticals to Webcast R&D Day on October 15, 2014
GlobeNewswire - Mon Oct 06, 8:33AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will webcast presentations at its Research and Development (R&D) Day on Wednesday, October 15, 2014, from 9:00 a.m. to approximately 12:00 p.m. EDT in New York City.
AGIO: 84.03 (-0.34)
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter
PR Newswire - Wed Oct 01, 7:55AM CDT
Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Amgen Inc. (NASDAQ: AMGN), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6893-100free.
BIIB: 321.08 (+0.08), BAX: 70.14 (+0.08), COV: 92.44 (+0.83), AMGN: 162.18 (+0.60), AGIO: 84.03 (-0.34)
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
MDVN: 105.70 (+2.96), GILD: 112.00 (-2.22), AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Critical Alerts For Invensense, Agios Pharmaceuticals, SPDR Gold Trust, Nu Skin Enterprises and Nike Released By InvestorsObserver
PR Newswire - Mon Sep 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for INVN, AGIO, GLD, NUS and NKE.
NKE: 92.97 (-0.03), NUS: 52.83 (+0.01), GLD: 112.66 (-2.53), INVN: 16.21 (+0.54), AGIO: 84.03 (-0.34)
Market Maker Surveillance Report. SKY, JNS, CNET, DGLY, AGIO, SFS, Winning Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Skyline Corp (NYSE:SKY), Janus Capital Group Inc (NYSE:JNS), Chinanet Online Holdings Inc (NASDAQ:CNET), Digital Ally Inc (NASDAQ
GLY), (NASDAQ:AGIO), (NYSE:SFS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . SFS: 14.75 (+0.75), SKY: 3.78 (-0.02), JNS: 14.99 (+0.32), AGIO: 84.03 (-0.34), CNET: 2.10 (-0.01), DGLY: 14.62 (-0.07)
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
MU: 33.09 (+1.27), HYG: 92.53 (+0.08), NKE: 92.97 (-0.03), XOP: 60.87 (+1.70), PFE: 29.95 (+0.11), BBRY: 10.50 (+0.02), XOM: 96.71 (+2.26), WYNN: 190.01 (+2.36), LVS: 62.26 (+0.76), MO: 48.34 (+0.84), BMY: 58.19 (-0.79), EWM: 15.37 (-0.04), TLT: 119.25 (-0.31), CELG: 107.09 (+0.15), JNK: 40.36 (unch), YHOO: 46.05 (+0.42), GILD: 112.00 (-2.22), AOL: 43.53 (+0.61), AGIO: 84.03 (-0.34), FL: 56.01 (+0.16), XLE: 87.42 (+1.74), BABA: 98.60 (-0.13)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Sep 26, 7:14PM CDT
Cramer will be looking for more opportunities, especially ones made better by any additional volatility.
F: 14.09 (+0.14), MKC: 70.72 (+0.86), NKE: 92.97 (-0.03), INVN: 16.21 (+0.54), M: 57.82 (-0.08), GLUU: 3.87 (+0.26), BWLD: 149.28 (-0.76), SLB: 98.66 (+1.04), YHOO: 46.05 (+0.42), ESRT: 15.96 (+0.05), AAPL: 108.00 (+1.02), WAG: 64.22 (+1.26), ECL: 111.23 (+2.88), HCP: 43.97 (+0.38), SWKS: 58.24 (+2.20), HAL: 55.14 (+1.22), STZ: 91.54 (+2.13), MGM: 23.25 (+0.27), FINL: 26.47 (+0.07), ADS: 283.35 (+0.38), TTWO: 26.45 (+1.18), WPG: 17.63 (+0.14), WEX: 113.56 (+2.31), KITE: 36.99 (+1.25), AOL: 43.53 (+0.61), FLT: 150.56 (+8.01), AGIO: 84.03 (-0.34), MRO: 35.40 (+1.29)
Agios drug data boosts stock
at Investor's Business Daily - Fri Sep 26, 5:52PM CDT
Biotech startup Agios Pharmaceuticals (AGIO) got a 19.3% boost to a new high of 63.76 after the company said that it would release key clinical trial data from its phase 1 study of blood cancer treatment AG-120 earlier than anticipated. It's...
AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Agios' Early Drug-Trial Report Cheers Wall Street
at Investor's Business Daily - Fri Sep 26, 12:21PM CDT
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good....
AGIO: 84.03 (-0.34), CELG: 107.09 (+0.15)
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 26, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NAII: 6.12 (+0.02), TNXP: 7.57 (-0.43), MSON: 13.36 (+0.08), RPRX: 6.34 (-0.41), CCRN: 9.67 (+0.06), AGIO: 84.03 (-0.34), CMSB: 12.90 (-0.10), DGLY: 14.62 (-0.07)
(0)
(0)Agios Pharmaceuticals Inc. (AGIO) Stock Research Links
Scroll down for more posts ▼